Substituted amide compounds useful as farnesoid X receptor modulators

US12319676B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Dean A. Wacker · Chadds Ford, US
• Susheel Jethanand Nara · Mumbai, IN
• Srinivas Cheruku · Bengaluru, IN
• Kandhasamy Sarkunam · Hosur, IN
• Firoz Jaipuri · Bengaluru, IN
• Soodamani Thangavel · Krishnagiri, IN
• Rishikesh Narayan · Mumbai, IN
• Srinivas Jogi · Kanchinakote, IN
• Pavan Kalyan Kathi · Kanchinakote, IN

Key dates

• Filing date: Feb 14, 2020
• Grant date: Jun 3, 2025
• Expiry date: Oct 3, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c, or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.